Form 4: Hologic Director Charles J. Dockendorff Reports Stock and Option Awards

Director Charles J. Dockendorff reports acquisition of restricted stock units and stock options in Hologic Inc.

Summary

• On February 26, 2025, Charles J. Dockendorff, a director of Hologic Inc., reported transactions involving Hologic's common stock and non-qualified stock options.
• Dockendorff acquired 1,864 restricted stock units (RSUs) which vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock.
• He also acquired 5,535 non-qualified stock options with an exercise price of $64.36, which become exercisable on the date of the 2026 Annual Meeting of Stockholders and expire on February 26, 2035.
• Following these transactions, Dockendorff directly owns 3,436 shares of common stock and indirectly owns 15,370 shares through a revocable trust.
• He also directly owns 5,535 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option awards, which is neither particularly positive nor negative on its own. The director's acquisition of shares and options suggests confidence, but it's a standard part of executive compensation.

Positives

• The acquisition of stock options and restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of RSUs and exercisability of stock options are tied to the 2026 Annual Meeting of Stockholders, suggesting a continued involvement and interest of the director in the company's performance until at least that date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The transactions reported may have a minor positive impact on shareholder sentiment, as they indicate the director's alignment with the company's long-term success.

Key Dates